#123FUZKK selection 101–300

Cellectis

France · European Union

Cell and gene therapyOncology / ADC / high-potencyFinished dosage forms and small molecules

Manufacturing profile

Country
France
Regulatory region
European Union
ISO
FRA

Selection basis

The company is placed in positions 101–300 as a manufacturer, biotechnology company, generics player or CDMO with practical relevance to the FUZKK utility catalog.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. The mapping does not claim actual use of FUZKK, a specific installed equipment model or a product not confirmed by the public company profile.

Representative manufacturing and QC chain

  1. 1Starting-material and cell-bank control
  2. 2Cell expansion or vector production
  3. 3Purification, concentration and formulation
  4. 4Identity, viability, potency and qPCR
  5. 5Sterility, endotoxin, environmental monitoring and chain of custody
  6. 6Contained dispensing and high-potency handling
  7. 7Chemical synthesis or biologic upstream
  8. 8Purification and formulation
  9. 9HPLC/LC-MS/CE and potency analytics

Relevant FUZKK packages

Lumex — instrumental QC

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. The mapping does not claim actual use of FUZKK, a specific installed equipment model or a product not confirmed by the public company profile.

Methodology